Shingles, of HZ. The clinical trials evaluated for

Shingles, also known as herpes zoster (HZ), is
an infection caused by the reactivation of varicella zoster virus that has
remained inactive in a person’s body after recovering from an initial chicken
pox infection. The incidence of shingles increases with age, with approximately
1 in 3 people in the general population developing the condition in their
lifetime. In the United States, approximately one million people will be
affected by shingles each year. Complications associated with shingles include
post-herpatic neuralgia (PHN), scarring, complications with vision, secondary
infections, and nerve palsies. PHN is the most common complication and can last
for months to years following an active infection. On October 20, 2017, the FDA
approved a new vaccination, Shingrix, for the prevention of HZ. The clinical
trials evaluated for its approval demonstrated an efficacy rate of
approximately 90% for individuals ? 50 years of age. This efficacy was also
demonstrated to be maintained 4 years after receiving the injection. Zostavax
is another commercially available product that is currently used to prevent HZ
infections in individuals ? 60 year of age. Its demonstrated efficacy rate is
approximately 51% with that number waning 5 years after the injection and
offering no protection after 8 years. As of October 25, 2017, the CDC’s
Advisory Committee on Immunization Practices (ACIP) has recommended the use of
Shingrix over Zostavax in immunocompetent individuals ? 50 years of age
regardless of previous immunization with Zostavax.